Services

Optimum Dosing Strategies’s ID – ODS design allows integration with a variety of third-party systems, giving health care practitioners vital access to the data they need at the point of care. Click here to contact us for further details about integrating ID – ODS into the workflow with your institutions electronic medical record.

Recharge

2012 – Farkas A, Successful target attainment of telavancin at elevated MICs: fact or fiction?  2012, Antimicrobial Agents and Chemotherapy, 56: 4560

More

ID-ODS 3.0: Bayesian dose optimization application…

ID-ODS 3.0: Bayesian dose optimization application…

ID-ODS 3.0 is finally released with the first drug module Vancomycin! The theme is focused around interactivity so don’t forget to “drag, drop, hover and click”! Sign up to join the growing number of community of Individually Designed Optimum Dosing Strategies, or ID-ODS users worldwide!

More

See recent publication on ID – ODS!

See recent publication on ID – ODS!

A review article published in May, 2020 in the journal Frontiers in Pharmacology indicates that ID-ODS is in a leading position versus its comparators for versatility, complexity and readiness for easy integration into clinical practice!.

More

ID – ODS transformation begun with Vancomycin!

ID – ODS transformation begun with Vancomycin!

We appreciate our patience during the process of transforming ID – ODS into the next generation interactive dose optimization application. The new platform is built on the bases of current functionalities with much improved user interface. Vancomycin module is released!

More

Manuscripts and Letters

2012 – Farkas A, Successful target attainment of telavancin at elevated MICs: fact or fiction?  2012, Antimicrobial Agents and Chemotherapy, 56: 4560

More

IDSA

2014 – Barry P.; Deck D.; Farkas A.; Pharmacokinetic modeling of linezolid dosing regimens for multidrug resistant tuberculosis

2013 – Farkas A, Rowin K; Pharmacodynamics of doripenem in critically ill patients: does race matter

More

ACCP

2012- Sussman R, Farkas A, Lee A, Evaluation of pharmacist managed vancomycin therapy compared to physician managed dosing in establishing timely and therapeutic vancomycin serum concentrations at a community hospital

2012 – Farkas A, Keren A, Hoffman C; Novel method to maximize levofloxacin pharmacodynamics for the treatment of systemic gram negative infections based on the population distribution of patient demographics at a community hospital

More

ECCMID

2014 – Farkas A, Daroczi G, Roberts J, Population Probability of Target Attainment of Colistin at Different Levels of Renal Function Against Pseudomonas aeruginosa and Acinetobacter baumanii in Europe

2014 – Farkas A, Daroczi G, Roberts J, Usage statistics of Individually Designed Optimum Dosing Strategies, a multi-model based online application to individualize antibiotic dosing in critically ill patients

More

ICAAC

2014 – Farkas A.; Saju S.; Gould P.; Kuriyilel J.; Villasurda P.; Roberts J.; Comparative evaluation of the performance of a population equation and two Bayesian methods to predict future Vancomycin concentrations .

2014 – Farkas A.; Villasurda P.; Feldfogel H.; Afroz S.; Evaluation Of The Safety And Efficacy Of Low Versus High Vancomycin Trough Levels For The Treatment Of Conditions Caused By Methicillin-Resistant Staphylococcus Aureus

More